Form 4: Pfizer Director Shantanu Narayen Reports Acquisition of Phantom Stock Units

Director Shantanu Narayen reports acquiring phantom stock units in Pfizer, according to a Form 4 filing with the SEC.

Summary

• Shantanu Narayen, a director of Pfizer Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 8,115.598 phantom stock units on April 25, 2024, at a price of $25.26 per unit.
• Following the transaction, Narayen directly owns 142,517.615 derivative securities.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock upon retirement from the Board of Directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a standard disclosure of director compensation. There are no particularly positive or negative implications.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The deferred compensation plan may incentivize continued service on the Board of Directors.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates compensation practices for non-employee directors at Pfizer.

Comparison to Industry Standards

• Deferred compensation plans, including phantom stock units, are a common practice among large publicly traded companies to attract and retain qualified non-employee directors.
• Companies like Johnson & Johnson and Merck also utilize similar compensation structures for their board members.
• The specific terms and conditions of these plans can vary, but the underlying goal is to align director compensation with shareholder value.

Stakeholder Impact

• The acquisition of phantom stock units by a director can positively influence shareholder confidence by aligning management's interests with those of the shareholders.

Key Dates